Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Kairos Pharma (KAPA) EBITDA Margin (2024 - 2025)

Historic EBITDA Margin for Kairos Pharma (KAPA) over the last 2 years, with Q1 2025 value amounting to 1.27%.

  • Kairos Pharma's EBITDA Margin fell 17950200.0% to 1.27% in Q1 2025 from the same period last year, while for Jun 2025 it was 4.58%, marking a year-over-year change of. This contributed to the annual value of 2.34% for FY2024, which is 40833000.0% down from last year.
  • Kairos Pharma's EBITDA Margin amounted to 1.27% in Q1 2025, which was down 17950200.0% from 71.32% recorded in Q3 2024.
  • Over the past 5 years, Kairos Pharma's EBITDA Margin peaked at 1850.0% during Q2 2024, and registered a low of 1.27% during Q1 2025.